Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia 2Hyperglycemia 2Lymphoma 1Leukemia, Myeloid, Acute 1Congenital Abnormalities 1Burkitt Lymphoma 1

Interventions

Cytarabine 13Daunorubicin 11Etoposide 7Filgrastim 5Peripheral Blood Stem Cell Transplantation 4Gemtuzumab 4valspodar 3Observation 3Mitoxantrone 3Busulfan 3sargramostim 2fludarabine phosphate 2aldesleukin 2Tretinoin 2Therapeutics 2Idarubicin 2Granulocyte Colony-Stimulating Factor 2Early Intervention, Educational 2Cyclophosphamide 2zosuquidar trihydrochloride 1midostaurin 1merphos 1laromustine 1etoposide phosphate 1dexamethasone acetate 1Whole-Body Irradiation 1Watchful Waiting 1Thioguanine 1Tacrolimus 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Congenital Abnormalities × Insulin Glargine × Clear all
NCT00943709 2013-08-30

Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia

Rutgers, The State University of New Jersey

Phase 3 Withdrawn
LymphoidOther hematologic neoplasm

Congenital Abnormalities, Hyperglycemia, Leukemia, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡